Guardant Health to Showcase 28 Abstracts on Tumor Typing and Liquid Biopsy Advances at AACR 2026
Event summary
- Guardant Health will present 28 abstracts, including 3 oral sessions, at AACR 2026, highlighting advances in tumor typing and liquid biopsy technology.
- Key data includes high accuracy of Guardant360 Tissue in determining tissue of origin with 92% accuracy across 6,000 samples and 24 tumor types.
- Guardant360 Liquid demonstrated actionable findings for 85% of metastatic breast cancer patients and 89% of advanced colorectal cancer patients.
- Guardant Reveal showed potential to detect new primary malignancies during minimal residual disease (MRD) monitoring.
- AACR 2026 will take place in San Diego, California, from April 17 to April 22, 2026.
The big picture
Guardant Health's presentation at AACR 2026 underscores the growing importance of liquid biopsy and multiomic testing in precision oncology. The company's focus on expanding the utility of its tests for tumor typing and therapy selection aligns with broader industry trends towards non-invasive, comprehensive genomic profiling. The strategic significance lies in Guardant Health's ability to address critical gaps in cancer care, potentially enhancing its market position and driving revenue growth.
What we're watching
- Clinical Adoption
- How the high accuracy rates of Guardant360 Tissue and the expanded utility of Guardant360 Liquid will affect clinical adoption and market penetration.
- Regulatory Approvals
- Whether Guardant Health can secure regulatory approvals for its advanced tumor typing and liquid biopsy technologies based on the presented data.
- Competitive Positioning
- The pace at which Guardant Health can differentiate itself from competitors in the precision oncology space with its multiomic tissue and liquid biopsy testing.
Related topics